Soussain C, et al. - In diffuse large B-cell lymphoma (DLBCL)-primary central nervous system lymphoma (PCNSLs), researchers assessed the effectiveness and toxicity of ibrutinib. Participants in this prospective, multicenter, phase 2 study were 52 patients with a relapse or refractory(R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma. The therapy consisted of ibrutinib (560 mg/day) until progression of the disease or occurrence of unacceptable toxicity. According to findings, ibrutinib has shown clinical activity in the brain, central nervous system, and intraocular compartment; it was also tolerated in R/R PCNSL. In the first-line treatment, the addition of ibrutinib to standard methotrexate-base induction chemotherapy will be further assessed. After two 28-day cycles, the intention-to-treat overall response rate was 52%, and the median progression-free survival was 4.8 months.